MOONLAKE IMMUNO (MLTX)
(Real Time Quote from BATS)
$50.66 USD
-0.38 (-0.75%)
Updated Sep 13, 2024 11:42 AM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Brokerage Reports
MoonLake Immunotherapeutics [MLTX]
Reports for Purchase
Showing records 81 - 96 ( 96 total )
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
We are initiating coverage with an OUTPERFORM rating and $33 twelvemonth PT.
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
KOL Call Reminder: Getting Under the Skin in HS & PsA
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Competitor Data Validates Sonelokimab Approach; 2022 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Looks Favorably Positioned Against Competitor; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Phase 2 Enrollment Completed Early; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Competitor Pivotal Data Bodes Well for Sonelokimab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Timelines On Track; 3Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Competitor Trial Halt Does Not Impact Sonelokimab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Competitor Skin Disease Data Does Not Impact Our Thesis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Clinical Programs Advancing; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Elevating Above Competitors in IL-17 Blockade; Initiating at Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R